Rate of Adverse Events in Clinical Trials of SGLT2 Inhibitors: Meta-analysis of RCTs

May 15-17, 2021; Virtual
In meta-analysis of 62 placebo-controlled RCTs, SGLT2 inhibitors were associated with increased risk of infection and diabetic ketoacidosis but showed similar rates of hypoglycemia, bone fracture, and amputations as placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 288 KB
Released: June 29, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From Clinical Care Options (CCO), new data in managing heart failure from ACC 2021

Lee R. Goldberg, MD, MPH, FACC James Udelson, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: July 28, 2021 Expired: July 27, 2022

Dr. Lee R. Goldberg discusses key studies from ACC 2021 that will impact heart failure management, as reported by Clinical Care Options (CCO)

Lee R. Goldberg, MD, MPH, FACC Released: July 15, 2021

From Clinical Care Options (CCO) and Dr. James Udelson, expert commentary on new data in heart failure management from ACC 2021

James Udelson, MD Released: July 14, 2021

From Clinical Care Options (CCO), new data from ACC 2021 on SGLT2 inhibitors in heart failure

Released: July 1, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue